Prevention and management of thromboembolism

Consultations in Feline Internal Medicine

Volumn , Issue , 2006, Pages 331-345

  Hogan, Daniel F ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882315777     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-72-160423-4/50040-8     Document Type: Chapter

References (131)

1. Harpster NK Feline myocardial diseases. Current veterinary therapy IX 1986, 380. WB Saunders, Philadelphia. R.W. Kirk (Ed.).
2. Bonagura JD, Fox PR Restrictive cardiomyopathy. Kirk's current veterinary therapy XII 1995, 863. WB Saunders, Philadelphia, . J.D. Bonagura (Ed.).
3. Laste NJ, Harpster NK A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977-1993. J Am Anim Hosp Assoc 1995, 31:492.
4. Atkins CE, Gallo AM, Kurzman ID, et al. Risk factors, clinical signs, and survival in cats with a clinical diagnosis of idiopathic hypertrophic cardiomyopathy: 74 cases (1985-1989). J Am Vet Med Assoc 1992, 201:613.
5. Baty CJ, Malarkey DE, Atkins CE, et al. Natural history of hypertrophic cardiomyopathy and aortic thromboembolism in a family of domestic shorthair cats. J Vet Intern Med 2001, 15:595.
6. Moore KE, Morris N, Dhupa N, et al. Retrospective study of streptokinase administration in 46 cats with arterial thromboembolism. J Vet Emerg Crit Care 2000, 10:245.
7. Rush JE, Freeman LM, Fenollosa NK, et al. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990-1999). J Am Vet Med Assoc 2002, 220:202.
8. Peterson EN, Moise NS, Brown CA, et al. Heterogeneity of hypertrophy in feline hypertrophic heart disease. J Vet Intern Med 1993, 7:183.
9. Smith SA, Tobias AH, Jacob KA, et al. Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med 2003, 17:73.
10. Hogan DF, Dhaliwal RS, Sisson DD, et al. Paraneoplastic thrombocytosis-induced systemic thromboembolism in a cat. J Am Anim Hosp Assoc 1999, 35:483.
11. Heffner RR Myopathy of embolic origin in patients with carcinoma. Neurology 1971, 21:840.
12. John WJ, Foon KA, Patchell RA Paraneoplastic syndromes. Cancer: principles and practice of oncology 1997, 2397. Lippincott-Raven, Philadelphia. ed 5. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
13. Bick RL, Strauss JF, Frenkel EP Thrombosis and hemorrhage in oncology patients. Heme Oncol Clin N Am 1996, 10:875.
14. McNiel EA, Ogilvie GK, Fettman MJ, et al. Platelet hyperfunction in dogs with malignancies. J Vet Intern Med 1997, 11:178.
15. Veterinary Medical Data Base. VMDB 1980-2003, July 2004. Accessed June 2004. http://www.vmdb.org.
16. Schoeman JP Feline distal aortic thromboembolism: a review of 44 cases (1990-1998). J Feline Med Surg 1999, 1:221.
17. Vinters HV, Jahan R Interactions between heart and brain. Cardiovascular pathology 2001, 471. Churchill Livingstone, Philadelphia. ed 3. M.D. Silver, A.I. Gotlieb, F.J. Schoen (Eds.).
18. Pathology of myocardial infarction. Cardiovascular pathology 2001, 155. WB Saunders, Philadelphia. ed 2. R. Virmani, A. Burke, A. Farb, J.B. Atkinson (Eds.).
19. Salgado ED, Furlan AJ, Conomy JP Cardioembolic sources of stroke. The heart and stroke 1987, 47. Springery-Verlag, London-Berlin. A.J. Furlan (Ed.).
20. Fuster V, Gersh BJ, Giuliani ER, et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981, 47:525.
21. Furlan AJ, Craciun AR, Raju NR, et al. Cerebrovascular complications associated with idiopathic hypertrophic subaortic stenosis. Stroke 1984, 15:282.
22. Helenski CA, Ross JN Platelet aggregation in feline cardiomyopathy. J Vet Intern Med 1987, 1:24.
23. Welles EG, Boudreaux MK, Crager CS, et al. Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease. Am J Vet Res 1994, 55:619.
24. Steele P, Rainwater J, Vogel R Abnormal platelet survival time in men with myocardial infarction and normal coronary arteriogram. Am J Cardiol 1978, 41:60.
25. Walsh PN, Kansu TA, Corbett JJ, et al. Platelets, thromboembolism and mitral valve prolapse. Circulation 1981, 63:552.
26. Horigome J, Hiramatsu Y, Shigeta O, et al. Overproduction of platelet microparticles in cyanotic congenital heart disease with polycythemia. J Am Coll Cardiol 2002, 39:1072.
27. 2 and prostacyclin in children with cyanotic congenital heart disease. Br Heart J 1993, 69:179.
28. Tanaka R, Yamane Y Platelet aggregation in dogs with mitral valve regurgitation. Am J Vet Res 2000, 61:1248.
29. Tanaka R, Murota A, Nagashima Y, et al. Changes in platelet life span in dogs with mitral valve regurgitation. J Vet Intern Med 2002, 16:446.
30. Longo G, Cecchi F, Grossi A, et al. Coagulation and platelet function in hypertrophic cardiomyopathy. Thromb Haemost 1984, 51:299.
31. Matsagas MI, Geroulakos G, Mikhailidis DP The role of platelets in peripheral arterial disease: therapeutic implications. Ann Vasc Surg 2002, 16:246.
32. Robless PA, Okonko D, Lintott P, et al. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 2003, 25:16.
33. Bisschops RH, Klijn CJ, Kappelle LJ, et al. Collateral flow and ischemic brain lesions in patients with unilateral carotid artery occlusion. Neurology 2003, 60:1435.
34. Kim JJ, Fischbein NJ, Lu Y, et al. Regional angiographic grading system for collateral flow: correlation with cerebral infarction in patients with middle cerebral artery occlusion. Stroke 2004, 35:1340.
35. Tohgi H, Takahashi S, Chiba K, et al. Cerebellar infarction. Clinical and neuroimaging analysis in 293 patients. The Tohoku Cerebellar Infarction Study Group. Stroke 1993, 24:1697.
36. Haimovici H Cardiogenic embolism of the upper extremity. J Cardiovasc Surg (Torino) 1982, 23:209.
37. Endys J, Hayat N, Cherian G Comparison of bronchopulmonary collaterals and collateral blood flow in patients with chronic thromboembolic and primary pulmonary hypertension. Heart 1997, 78:171.
38. Todd MH, Forrest JB, Cragg DB The effects of aspirin and methysergide on responses to clot-induced pulmonary embolism. Am Heart J 1983, 105:769.
39. Schaub RG, Meyers KM, Sande RD, et al. Inhibition of feline collateral vessel development following experimental thrombotic occlusion. Circ Res 1976, 39:736.
40. Butler HC An investigation into the relationship of aortic emboli to posterior paralysis in the cat. J Small Anim Pract 1971, 12:141.
41. Imhoff RK Production of aortic occlusion resembling acute aortic embolism syndrome in cats. Nature 1961, 192:979.
42. Olmstead ML, Butler HC Five-hydroxytryptamine antagonists and feline aortic embolism. J Small Anim Pract 1977, 18:247.
43. Fu LW, Longhurst JC Activated platelets contribute to stimulation of cardiac afferents during ischaemia in cats: role of 5-HT3 receptors. J Physiol 2002, 544:897.
44. Schaub RG, Gates KA, Roberts RE Effect of aspirin on collateral blood flow after experimental thrombosis of the feline aorta. Am J Vet Res 1982, 43:1647.
45. De Clerk F, Loots W, Somers Y, et al. 5-Hydroxytryptamine and arachidonic acid metabolites modulate extensive platelet activation induced by collagen in cats in vivo. Br J Pharmacol 1990, 99:631.
46. McKenzie ME, Malinin AI, Bell CR, et al. Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. Blood Coagul Fibrinolysis 2003, 14:249.
47. Green HW, Hogan DF Suspected iatrogenic paradoxical embolism in a cat. J Am Anim Hosp Assoc 2005, 41:193.
48. Fox PR Feline cardiomyopathies. Textbook of canine and feline cardiology: principles and clinical practice 1999, 621. WB Saunders, Philadelphia. ed 2. P.R. Fox, D.D. Sisson, N.S. Moise (Eds.).
49. Pion PD, Kittleson MD Therapy for feline aortic thromboembolism. Current veterinary therapy X 1989, 295. WB Saunders, Philadelphia. R.W. Kirk (Ed.).
50. Messmore HL, Griffin B, Fareed J, et al. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann N Y Acad Sci 1989, 556:217.
51. Reininger CB, Greinacher A, Graf J, et al. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res 1996, 81:641.
52. Burgess JK, Chong BH The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 1997, 58:279.
53. Mikhailidis DP, Barradas MA, Jeremy JY, et al. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest 1985, 15:313.
54. Smith SA, Lewis DC, Kellerman DL: Adjustment of intermittent subcutaneous heparin therapy based on chromogenic heparin assay in 9 cats with thromboembolism. Proc 16th Ann Vet Med Forum, 1998, p 690 (abstract).
55. Goodman JS, Rozanski EA, Brown D, et al. The effects of low-molecular weight heparin on hematologic and coagulation parameters in normal cats. Proc 17th Ann Vet Med Forum 1999, 733.
56. DeFrancesco TC, Moore RR, Atkins CE, et al: Comparison of dalteparin and warfarin in the long-term management of feline arterial thromboembolism. Proc 21st Ann Vet Med Forum, 2003, p 1022 (abstract).
57. Ramsey CC, Riepe RD, Macintire DK, et al. Streptokinase: a practical clot-buster?. Proc 5th Internat Vet Emerg Crit Care Symp 1996, 225.
58. Pion PD, Kittleson MD, Peterson S, et al: Thrombolysis of aortic thromboemboli in cats using tissue plasminogen activator: clinical data. Proc 5th Ann Vet Med Forum, 1987, p 925 (abstract).
59. Hogan DF: Unpublished data.
60. Wilcke JR Idiosyncracies of drug metabolism in cats. Effects on pharmacotherapeutics in feline practice. Vet Clin North Am Small Anim Pract 1984, 14:1345.
61. Davis LE Clinical pharmacology of salicylates. J Am Vet Med Assoc 1980, 176:65.
62. Hogan DF, Andrews DA, Green HW, et al. The pharmacodynamics and platelet responses to clopidogrel in cats. J Am Vet Med Assoc 2004, 225:1406.
63. Arrebola MM, De la Cruz JP, Villalobos MA, et al. In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J Cardiovasc Pharmacol 2004, 43:74.
64. Yang LH, Fareed J Vasomodulatory action of clopidogrel and ticlopidine. Thromb Res 1997, 86:479.
65. Yang LH, Hoppensteadt D, Fareed J Modulation of vasoconstriction by clopidogrel and ticlopidine. Thromb Res 1998, 92:83.
66. Umemura K, Ishihara H, Nakashima M Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thromb Res 1995, 80:209.
67. Bednar MM, Quilley J, Russell SR, et al. The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke. Neurosurgery 1996, 39:352.
68. Boneu B, Destelle G Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996, 76:939.
69. Coukell AJ, Markham A Clopidogrel. Drugs 1997, 54:745.
70. Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000, 101:2823.
71. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001, 85:92.
72. Matsagas M, Jagroop IA, Geroulakos G, et al. The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. Clin Appl Thromb Hemost 2003, 9:115.
73. Veterinary drug handbook 2002, Iowa State Press, Ames, Iowa. ed 4. D.C. Plumb (Ed.).
74. Harpster NK, Baty CJ Warfarin therapy of the cat at risk of thromboembolism. Current veterinary therapy XII 1995, 868. WB Saunders, Philadelphia. J.D. Bonagura (Ed.).
75. collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994, 308:81. Antiplatelet Trialists' Collaboration.
76. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994, 343:687.
77. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. Br Med J 1999, 319:958.
78. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989, I:175.
79. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991, 84:527.
80. Cundiff DK Anticoagulants for nonvalvular atrial fibrillation (NVAF): drug review. Med Gen Med 2003, 5:4.
81. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993, 342:1255.
82. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996, 348:633.
83. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction predicts stroke following myocardial infarction. N Engl J Med 1997, 336:251.
84. Dries DL, Rosenberg Y, Waclawiw M, et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997, 29:1074.
85. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991, 325:1261. Dutch TIA Trial Study Group.
86. Greene CE Effects of aspirin and propranolol on feline platelet aggregation. Am J Vet Res 1985, 46:1820.
87. Behrend EN, Grauer GF, Greco DS, et al. Comparison of the effects of diltiazem and aspirin on platelet aggregation in cats. J Am Anim Hosp Assoc 1996, 32:11.
88. Allen DG, Johnstone IB, Crane S Effects of aspirin and propranolol alone and in combination on hemostatic determinants in the healthy cat. Am J Vet Res 1985, 46:660.
89. McTavish D, Faulds D, Goa KL Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet dependent disorders. Drugs 1990, 40:238.
90. Di Minno G, Cerbone AM, Mattioli PL, et al. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985, 75:328.
91. Lerner RG, Frishman WH, Mohan KT Clopidogrel: a new antiplatelet drug. Heart Dis 2000, 2:168.
92. Gachet C Platelet activation by ADP: the role of ADP antagonists. Ann Med 2000, 32(suppl 1):15.
93. Fareed J, Messmore HL Clopidogrel. Semin Thromb Hemost 1999, 25:1.
94. Cattaneo M, Lombardi R, Bettega D, et al. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb Vasc Biol 1993, 13:393.
95. Hogan DF, Andrews DA, Talbott KK, et al. Evaluation of antiplatelet effects of ticlopidine in the cat. Am J Vet Res 2004, 65:327.
96. Picard-Fraire C Ticlopidine hydrochloride: relationship between dose, kinetics, plasma concentration and effect on platelet function. Thromb Res Suppl 1983, 4:119.
97. Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992, 44:527.
98. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000, 84:891.
99. Gent M, Blakely JA, Easton JD, et al. The Canadian American ticlopidine study (CATS) in thromboembolic stroke. Lancet 1989, 1:1215.
100. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989, 321:501.
101. Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329.
102. Kuzniar J, Splawinska B, Malinga K, et al. Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition. Int J Clin Pharmacol Ther 1996, 34:357.
103. Goyan JE Ticlopidine: quo vadis? Adverse reactions in man. Agents Actions 1984, 15(suppl):116.
104. Bennett CL, Weinberg PD, Rozenberg K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 1998, 128:541.
105. Harker LA, Boissel JP, Pilgrim AJ, et al. Comparative safety and tolerability of clopidogrel and aspirin (Results from CAPRIE). Drug Safety 1999, 21:325.
106. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000, 342:1773.
107. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990, 323:1505. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.
108. Hogan DF: Unpublished results.
109. Connolly SJ, Laupacis A, Gent M, et al. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991, 18:349.
110. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992, 327:1406.
111. Gulløv AL, Koefold BG, Petersen P Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation. Arch Intern Med 1999, 159:1322.
112. Smith SA, Kraft SL, Lewis DC, et al. Plasma pharmacokinetics of warfarin enantiomers in cats. J Vet Pharmacol Therap 2000, 23:329.
113. Smith SA, Kraft SL, Lewis DC, et al. Pharmacodynamics of warfarin in cats. J Vet Pharmacol Therap 2000, 23:339.
114. Armstrong P Heparin in acute coronary disease: requiem for a heavyweight?. N Engl J Med 1997, 337:492.
115. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Lancet 1996, 347:561.
116. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997, 96:61.
117. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997, 337:447.
118. FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999, 354:701. Long-term low-molecular-mass heparin in unstable coronary-artery disease.
119. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997, 337:657.
120. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998, 339:80.
121. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999, 341:793.
122. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch Intern Med 2000, 160:2199.
123. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med 2000, 160:2208.
124. Kontny F, Dale J, Abildgaard U, et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997, 30:962.
125. Alwood AJ, Downend AB, Brooks MB, et al. Anticoagulant effects of low molecular weight heparin in healthy cats. J Vet Emerg Crit Care (abstract) 2004, 14:S1.
126. Fareed J, Walenga JM, Kumar A A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemost 1985, 11:155.
127. Harenberg J, Stehle G, Blauth M, et al. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis. Semin Thromb Hemost 1997, 23:83.
128. Morris TA Heparin and low molecular weight heparin: background and pharmacology. Clin Chest Med 2003, 24:39.
129. Lorenzoni R, Lazzerini G, Cocci F, et al. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the clopidogrel-aspirin atrial fibrillation (CLAAF) pilot study. Am Heart J 2004, 148:e6.
130. Smith CE, Rozanski EA, Freeman LM, et al. Use of low molecular weight heparin in cats: 57 cases (1999-2003). J Am Vet Med Assoc 2004, 225:1237.
131. Hogan DF. Unpublished data.